Remove tag combination-product-development
article thumbnail

Grand Rounds January 26, 2024: Advancing the Safe, Effective and Equitable Use of AI in Healthcare (Mark Sendak, MD, MPP; Suresh Balu, MD, MBA)

Rethinking Clinical Trials

DIHI approaches this work through four pillars of innovation: implementation and health delivery science, health technology innovation, leadership and workforce development, and best practices development and dissemination. Key decision point 1 is procurement. The next key decision point is clinical integration.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

Combining data from all markets, efficacy-related needs were identified as the most important unmet needs category. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy. Cost-related unmet needs also scored highly.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Both drugs come with a high price tag. On the opposing side, Sanofi argues that Amgen’s approach not only violates enablement requirements, but also stifles innovation by stopping others from developing new therapeutics, says Falati.

Antibody 262
article thumbnail

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

The Pharma Data

Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines.

article thumbnail

Further insight into breakthroughs in mRNA drug discovery 

Drug Discovery World

DDW recently hosted Where are the breakthroughs in mRNA drug discovery and development? In this webinar, sponsored by Elegen, attendees learnt about the breakthroughs in mRNA drug discovery and development. We have shown that the excipient does not only work for our SNAP-tag lipid (SNaP) LNP, but also for the commercialised vaccines.

Drugs 52
article thumbnail

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.” Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. —- End —-.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Automation can be such a solution. Reducing capacity issues. Cutting down on safety stock.